Chongqing Genrix Biopharmaceutical Co., Ltd.SSE: 688443

(688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Report for Q3 2026

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688443 · · 14 pages · Chinese

Summary by 6ix AI

The report confirms that the financial data presented is accurate and complete, with the board of directors taking legal responsibility for its contents. Key financial highlights include significant increases in revenue and net profit compared to the same period last year, driven by strong sales of new products and licensing agreements. The report also notes ongoing progress in several research projects and regulatory approvals for new drug applications.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix

Earlier from Chongqing Genrix Biopharmaceutical

Later from Chongqing Genrix Biopharmaceutical

All Chongqing Genrix Biopharmaceutical news releases